<DOC>
	<DOC>NCT00499707</DOC>
	<brief_summary>The purpose of this 32 week study is to demonstrate that fixed-dose combination treatment with rosiglitazone/metformin will safely and effectively control glycemia as first line oral therapy in subjects type 2 diabetes. The primary objective of the study is to demonstrate superiority of rosiglitazone/metformin compared to its rosiglitazone and metformin.</brief_summary>
	<brief_title>Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>18 to 70 years of age Clinical diagnosis of type 2 diabetes HbA1c &gt;7.5% to 11% FPG &lt;270mg/dL (15mmol) Current treatment with diet and/or exercise alone, or no more than 15 days of an antidiabetic medication or insulin within 12 weeks of screening Clinically significant renal or hepatic disease Presence of anemia Presence of unstable or severe angina, coronary insufficiency, or any congestive heart failure requiring therapy Systolic blood pressure &gt;170mmHg or diastolic blood pressure &gt;100mmHg, while on antihypertensive treatment Chronic disease requiring intermittent or chronic treatment with corticosteroids Any female lactating, pregnant, or planning to become pregnant History of hepatocellular reaction, severe edema or a medically serious fluid related event associated with any thiazolidinedione Presence of acute or chronic metabolic acidosis History of diabetic ketoacidosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HbA1c</keyword>
	<keyword>Drug-naive</keyword>
	<keyword>type 2 diabetes</keyword>
</DOC>